Open-label Ziprasidone Study for Psychosis Treatment in Adolescents
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
This open-label study will assess the medication Geodon® (Ziprasidone) in pediatric patients,
aged 13-17, diagnosed with psychotic disorder. Eligible adolescents will receive Geodon® for
7 weeks and stay at the NYSPI Children's Day Unit (CDU) during the day. If clinically
appropriate, they may also stay at the New York State Psychiatric Institute (NYSPI)
Schizophrenia Research Unit (SRU) inpatient facility.